PharmaNet Development Group Inc, a provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announces that Chris Beaver, PhD has joined the Company as Director, Immunochemistry Services. Dr Beaver is responsible for leading the immunochemistry team within the Company's bioanalytical laboratories and expanding its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.
"We are very excited to have Chris joining us," said Dr. Richard LeLacheur, Vice President. "Chris brings to PharmaNet a combination of CRO leadership experience and technical expertise in large molecule bioanalysis that enhances our ability to support the drug development strategies of our clients. He is a valuable addition to our bioanalytical team."
Dr Beaver's appointment strengthens PharmaNet's offerings in large molecule bioanalytical services to support the growing interest in biologics and biosimilars within the pharmaceutical industry. PharmaNet has two GLP-compliant bioanalytical laboratories which are located in Princeton, New Jersey and Quebec City, Canada.
Previously, Dr. Beaver served as Scientific Director of Ligand Binding/Cell Based Assays at another clinical research organization with macromolecule bioanalysis operations. He completed his Ph.D. in Neuroscience at Dalhosie University in Halifax, Canada, followed by post-doctoral training at Yale University. Dr. Beaver is published in multiple scientific publications, including Drug Discovery World and Nature Neuroscience.
PharmaNet Development Group Inc
